Lactate


Cat. No.: HY-B2227 CAS No.: 50-21-5 Molecular Formula:  $C_3H_6O_3$ Molecular Weight: 90.08

Target: **Endogenous Metabolite** Pathway: Metabolic Enzyme/Protease Storage: Pure form -20°C

3 years 4°C 2 years

-80°C In solvent 6 months

> -20°C 1 month



**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (1110.12 mM; Need ultrasonic) H<sub>2</sub>O: 100 mg/mL (1110.12 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	11.1012 mL	55.5062 mL	111.0124 mL
	5 mM	2.2202 mL	11.1012 mL	22.2025 mL
	10 mM	1.1101 mL	5.5506 mL	11.1012 mL

Please refer to the solubility information to select the appropriate solvent.

# **BIOLOGICAL ACTIVITY**

Description	Lactate (Lactic acid) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactate is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactate is an oncometabolite and has immune protective role of lactate in anti-tumor immunity <sup>[1][2]</sup> .		
IC <sub>50</sub> & Target	Human Endogenous Metabolite		
In Vitro	Lactate (Lactic acid; 20 mM; 24, 48 h) results in a significant decrease in cell proliferation and migration, acting and switching cell metabolism toward oxidative phosphorylation <sup>[1]</sup> .  Lactate (20 mM; 24 h) shows an increase in the protein and mRNA expression levels of MCT1 and HCAR1 <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.  Cell Proliferation Assay <sup>[1]</sup> Cell Line:  Uveal melanoma 92.1 cells		

Concentration:	20 mM	
Incubation Time:	24, 48 h	
Result:	Inhibited cell proliferation and migration.	
Western Blot Analysis <sup>[1]</sup>		
Cell Line:	Uveal melanoma cells	
Concentration:	20 mM	
Incubation Time:	24 h	
Result:	Showed an increase in the protein expression levels of MCT1 and HCAR1	
Western Blot Analysis <sup>[1]</sup>		
Cell Line:	Uveal melanoma cells	
Concentration:	20 mM	
Incubation Time:	24 h	
Result:	Induced a significant increase in mRNA expression levels of SLC16A1 and HCAR1.	

### In Vivo

Lactate (Lactic acid; 1.6 g/kg; subcutaneous; daily from Day 8 to 30 days) shows CD8+ T cell-dependent tumor growth inhibition in MC38 colon cancer model  $^{[2]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female C57BL/6 mice with MC38 colon cancer cells <sup>[2]</sup>	
Dosage:	1.6 g/kg	
Administration:	Subcutaneous; daily from Day 8 to 30 days	
Result:	Significantly suppressed tumor growth.	

## **CUSTOMER VALIDATION**

• Cell Res. 2023 Jul 13.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

### **REFERENCES**

[1]. Lucia Longhitano, et al. Lactate Rewrites the Metabolic Reprogramming of Uveal Melanoma Cells and Induces Quiescence Phenotype. Int J Mol Sci. 2022 Dec 20;24(1):24.

[2]. Qiang Feng, et al. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat Commun. 2022 Sep 6;13(1):4981.

Page 2 of 3 www.MedChemExpress.com

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 3 of 3 www.MedChemExpress.com